Johanna Hynninen - Gynecology

Author Information

Johanna Hynninen is affiliated with the Department of Obstetrics and Gynecology at Turku University Hospital and the University of Turku in Turku, Finland. Her research predominantly focuses on gynecological oncology, particularly ovarian and cervical cancers. She has made significant contributions to the understanding of chemoresistance, tumor hypoxia, and diagnostic imaging in gynecological malignancies.

Research Contributions

Johanna Hynninen has authored numerous papers that delve into various aspects of gynecological cancers. Her recent work includes the development of frameworks for RNA in situ hybridization image analysis, longitudinal single-cell RNA sequencing for studying chemoresistance in metastatic ovarian cancer, and the establishment of platforms for drug response profiling of ovarian cancer organoids. Additionally, she has investigated novel prognostic factors in ovarian cancer, advanced imaging techniques for tumor hypoxia, and tools for fusion gene integration. Her research aims to improve diagnostic and therapeutic strategies in gynecological oncology.

Aliases

Johanna Hynninen is also known as J. Hynninen.

Publication and Citation Metrics

Metric	Value
Citation Count	1079
h-index	19
Paper Count	103

Publications:

QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability

DOI: 10.1038/s41374-022-00743-5

Year: 2022

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer

DOI: 10.1126/sciadv.abm1831

Year: 2022

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

DOI: 10.1101/2022.04.21.489027

Year: 2022

Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer

DOI: 10.1097/RLU.0000000000003914

Year: 2021

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

DOI: 10.3390/cancers13081764

Year: 2021

FUNGI: FUsioN Gene Integration toolset

DOI: 10.1093/bioinformatics/btab206

Year: 2021

Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality

DOI: 10.1038/s41598-021-88382-6

Year: 2021

Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance

DOI: 10.1038/s41467-021-24009-8

Year: 2021

Diagnostic efficiency of whole-body 18F-FDG PET/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer

DOI: 10.1186/s40644-020-00372-5

Year: 2021

Optimized detection of somatic allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in ovarian cancer

DOI: 10.1101/2021.08.19.456809

Year: 2021

What is Pseudohypoparathyroidism?

What are Pharmacologic Interventions?

What is the Oral Examination Like?

What is Physical Therapy in Gynecology?

How do Vaccinations Help?

What is the future outlook for funding in gynecology?

How does menopause affect mood?

What treatment options are available for women with ITP?

How Can Gynecological Surgeries Impact Urinary Function?

Can Sex Toys Improve Intimacy in Relationships?

Partnered Content Networks

Relevant Topics